Search

Your search keyword '"Sampogna, Francesca"' showing total 442 results

Search Constraints

Start Over You searched for: Author "Sampogna, Francesca" Remove constraint Author: "Sampogna, Francesca"
442 results on '"Sampogna, Francesca"'

Search Results

6. Itch and Mental Health in Dermatological Patients across Europe: A Cross-Sectional Study in 13 Countries

7. Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS)

14. Human papillomavirus and posttransplantation cutaneous squamous cell carcinoma: A multicenter, prospective cohort study

15. Emotions at diagnosis in patients with bullous diseases

16. Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)

17. Perceived Stigmatization among Dermatological Outpatients Compared with Controls: An Observational Multicentre Study in 17 European Countries

18. White paper on psychodermatology in Europe: A position paper from the EADV Psychodermatology Task Force and the European Society for Dermatology and Psychiatry (ESDaP).

21. Supplementary Table 2 from Identification of Key Regions and Genes Important in the Pathogenesis of Sézary Syndrome by Combining Genomic and Expression Microarrays

22. Supplementary Table 1 from Identification of Key Regions and Genes Important in the Pathogenesis of Sézary Syndrome by Combining Genomic and Expression Microarrays

23. Data from Identification of Key Regions and Genes Important in the Pathogenesis of Sézary Syndrome by Combining Genomic and Expression Microarrays

24. Supplementary Figure 1 from Identification of Key Regions and Genes Important in the Pathogenesis of Sézary Syndrome by Combining Genomic and Expression Microarrays

25. Supplementary Table 3 from Identification of Key Regions and Genes Important in the Pathogenesis of Sézary Syndrome by Combining Genomic and Expression Microarrays

26. Supplementary Table 4 from Identification of Key Regions and Genes Important in the Pathogenesis of Sézary Syndrome by Combining Genomic and Expression Microarrays

27. Supplementary Figure 2 from Identification of Key Regions and Genes Important in the Pathogenesis of Sézary Syndrome by Combining Genomic and Expression Microarrays

28. Genome Data Link from Identification of Key Regions and Genes Important in the Pathogenesis of Sézary Syndrome by Combining Genomic and Expression Microarrays

29. Skin pain: A symptom to be investigated

30. Which Health-Related Quality of Life Items Most Affect Acne Patients?

32. Testing some psychometric properties of the Italian version of the Skin Cancer Index: A questionnaire for measuring quality of life in patients with non-melanoma skin cancer

33. Quality of life measurement in vitiligo. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes with external experts

34. Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study— IL PSO ( Italian landscape psoriasis )

35. A consensus-based approach on the management of patients with both psoriasis and psoriatic arthritis in the dermatological and rheumatological settings in Italy: The ADOI PSO-Amore Project

37. Real life long‐term efficacy and safety of ixekizumab in moderate‐to‐severe psoriasis: A 192 weeks multicentric retrospective study— IL PSO ( Italian landscape psoriasis)

39. Which Health-Related Quality of Life Items Most Affect Acne Patients?

40. Body dysmorphia in common skin diseases: Results of an observational, cross-sectional multi-centre study among dermatological out-patients in 17 European countries

41. Attitudes among dermatologists regarding actinic keratosis treatment options

42. Sentiments de culpabilité chez les parents d’enfants atteints de dermatite atopique

44. Perception de la sévérité clinique de la dermatite atopique chez l’enfant : comparaison entre l’évaluation des patients et celle des parents

45. Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis).

46. Quality of life measurement in vitiligo. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes with external experts.

49. Attitudes Among Dermatologists Regarding Actinic Keratosis Treatment Options

Catalog

Books, media, physical & digital resources